

## Economics

11 May 2012 | 12 pages

# UK Economics Weekly

## Options for Extra Stimulus


- At present there seems to be a sense of powerlessness among UK policymakers, faced with the stagnant economy, headwinds from the simultaneous deleveraging of private and public sectors plus the worsening EMU crisis. This week's data confirm that industrial production and construction output both fell in Q1 and have achieved little or no overall growth over the last 10 years. It is not clear if policymakers yet believe that extra stimulus is needed. But we expect the forthcoming *Inflation Report* will signal that further QE is still an option if growth prospects worsen and inflation slows. We continue to expect that QE will be expanded markedly further.
- There also are a range of other policy measures that could be used if the economy continues to disappoint or the EMU crisis escalates rapidly. These include a lower Bank Rate, credit easing, temporary fiscal stimulus and supply-side reform, especially to encourage firms to hire younger people. Some of these could usefully be implemented now in our view, while others are in the toolbox — and may be needed at short notice — especially if the EMU crisis worsens rapidly. However, we believe FX intervention to cap sterling is unlikely unless outright deflation threatens.

Figure 1. Citigroup Market Forecasts

	Base Rate	QE Target	10 Year Yield	Spread vs Bunds	\$/£	£/€
Mid 2012	0.50	£325bn	2.10	35bp	1.57	0.83
End Q1 2013	0.50	£500bn	2.20	40bp	1.54	0.82

Source: Citi Investment Research and Analysis

Figure 2. UK — Cumulative Change in Industrial Production and Construction Output Since Q1-2002, 2002-12



Sources: ONS and Citi Investment Research and Analysis

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

**Michael Saunders**

+44-20-7986-3299

michael.saunders@citi.com

**Ann O'Kelly**

+44-20-7986-3297

ann.okelly@citi.com

For all distribution enquiries regarding

Citi Economics research, including

access via Citi websites and via

third party distribution channels, please

contact michael.saunders@citi.com

or jan.maguire@citi.com

Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## Options for Extra Stimulus

**We lay out options for extra stimulus for the UK if the economy continues to disappoint or the EMU crisis escalates**

At present there seems to be a sense of powerlessness among UK policymakers, faced with the stagnant economy, worsening EMU crisis, plus headwinds from the simultaneous deleveraging of private and public sectors. It is not clear if policymakers believe that extra stimulus is needed yet, but this note aims to lay out options. These can be divided into measures to slow the pace of private sector deleveraging (QE, lower Bank Rate, credit easing); to support exports (weaker pound); to slow the pace of public sector deleveraging (temporary fiscal stimulus); and to improve the economy's dynamism (supply-side reform). Clearly, there is some overlap (eg QE cuts debt service costs and thus indirectly allows extra public spending within the fiscal targets). Some of these could usefully be implemented now in our view, while others are in the toolbox — and may be needed at short notice — if the economy continues to disappoint or the EMU crisis worsens rapidly<sup>1</sup>.


**We expect the *Inflation Report* will signal that the door to further QE remains open**

**More QE.** Although the MPC have ended the existing QE programme at £325bn, we believe that extra QE is still likely. Indeed, we expect MPC to signal in the upcoming *Inflation Report* that the door remains open to further QE. The Governor may make this clear in the press conference, or the MPC may signal their thinking indirectly, by forecasting that the current policy stance will probably leave inflation below target 2-3 years ahead. The MPC could then restart QE in coming months (even in June or July) if data or the EMU crisis justify. To be sure, the scale of stimulus from QE is uncertain, but the MPC have been clear that on balance they believe QE does support growth rather than hinder it<sup>2</sup>. Moreover, although gilt yields are the lowest for many decades, they could still be pushed down further by QE.

**The MPC believe that setting Bank Rate below 0.5% might produce undesirable negative interest rates or a squeeze on bank profits...**


**Cut Bank Rate.** The MPC's decision to not cut rates below 0.5% in 2009 seemed to reflect worries that a lower Bank Rate would lead to undesirable negative interest rates on household deposits or some tracker mortgages (which were available at below Bank Rate in the boom), and that such negative interest rates would be undesirable. Even if one accepts the premise that negative interest rates are undesirable (and that is debatable in our view), these objections carry less weight now than in 2009.

**Figure 3. UK — BoE Bank Rate and Key Household Deposit Rates, 2009-12**



Sources: BoE and Citi Investment Research and Analysis

**Figure 4. UK — Average Interest Rates on Variable Rate Mortgages, 2004-12**



Sources: BoE and Citi Investment Research and Analysis

<sup>1</sup> Some of these options are covered also in "Global Economics View: What More Can Central Banks Do To Stimulate the Economy?," Willem Buiter and Ebrahim Rahbari, 9 May 2011, Citi.

<sup>2</sup> See, for example, the article by BoE Deputy Governor Charlie Bean in the Financial Times, Friday 4 May 2012.

...but in practice retail deposit rates are rising...

■ BoE data show that the average interest rate on interest-bearing sight deposits has risen from about 0.7% in 2009 to 1.0% now, while the average interest rate on sterling ISA (ie tax free) deposits is up from 0.4% to 0.65%, and the average rate on sterling time deposits is up from 0.2% to 1.3%. If the BoE cut rates by 25bp and it was fully passed on, none of these deposit rates would go negative. Conversely, rising deposit rates are now being passed on to higher mortgage rates, hence tightening financial conditions.

...and there do not seem to be many sub-Bank Rate tracker mortgages left

■ We cannot find data on the number of tracker mortgages fixed below Bank Rate. But, it does not appear that such loans are widespread. BoE data show that the average interest rate charged on the stock of outstanding variable rate mortgages was 3.1% in March, 2.6% above Bank Rate — and this spread has risen markedly in recent years (as spreads on new loans have increased). The issue of negative rates on a few Tracker Mortgages appears trivial in our view.


The option of cutting Bank Rate is worth re-examining in our view

To be sure, one could argue that a cut in Bank Rate to 25bp, or even 10bp, would only yield modest stimulus. But, if more stimulus is needed, then every little helps.

Credit availability is poor, with wide lending spreads and tough extra conditions


**Credit easing.** Although riskless rates are ultra-low, many private sector interest rates have wide spreads over riskless rates. For example, over the last six months, average spreads over swap rates on new 2-year fixed mortgages (75% LTV) have risen by 68bp, spreads on 5-year fixed mortgages (75% LTV) have risen by 53bp and spreads on new tracker mortgages have risen by 33bp. Average interest rates on bank overdrafts (a key form of finance for small firms) are 19.5%, the highest since data began in 1995. The average interest rate on a £5,000 unsecured personal bank loan has risen to 15.8% from 8.7% five years ago. The average interest rate on loans to SMEs of turnover below £1million is 4.8% now versus 3.7% in mid-09. Moreover, there are other constraints on credit availability: for example, the average LTV on mortgage loans for first-time buyers is only 80%, versus the pre-crisis norm of 90-95%. As a result, the average deposit among FTBs equals 81% of annual income, versus 10-15% in the mid-90s (the last housing slide).

Figure 5. UK — Average Spreads (Over Bank Rate) on Loans to Small Firms, 2004-2012



Note: Smaller SMEs have turnover of less than £1million per year.  
Sources: BoE, Datastream and Citi Investment Research and Analysis

Figure 6. UK — Average Mortgage Payments and Deposit (as pct income) Among First-Time Buyers, 1980-2012



Sources: CML and Citi Investment Research and Analysis

**The wide level of lending spreads is unlikely to fade spontaneously soon**

Normal market forces are unlikely to produce a significant improvement in credit availability in the year ahead in our view. The wide level of lending spreads is rational from banks' point of view: they are under pressure to lift capital ratios and cut wholesale funding, and face uncertainties over credit quality given the high level of private debt and weak economy. But, the aggregate effect is to reinforce the weakness of the economy. Last year's "Project Merlin" failed to tackle this: the banks in aggregate hit their targets by making credit available at high interest rates and with tough collateral terms — and lending to small firms fell.

**Credit easing can be achieved, if necessary by simply using the state-owned banks**

The Chancellor announced plans to subsidise loans to SMEs in the Budget. But, if this does not improve things dramatically, more may need to be done. One option would be to cut bank capital charges for selected loan categories<sup>3</sup>, but this cuts against the internationally-agreed Basel standards and the UK's aim of setting capital ratios above those norms. Or the BoE could provide banks with cheap long-term funding, like the ECB's 3-year LTRO programme, although so far the ECB's LTROs have not fed through to lower private sector borrowing costs. Other options — which probably would be more effective in our view — would be for the BoE to buy packages of securitized new SME loans at low yields, or for the government to simply order the state-owned banks to lend to UK SMEs at ultra-low rates. Of course, such measures may have a fiscal cost. But this may be no higher than the fiscal cost if policy inaction prolongs economic weakness.

**Although the aggregate UK unemployment rate has risen quite modestly, there is a serious unemployment crisis among younger people**

**Supply side measures**, which may give some nearterm stimulus, but — at least as importantly — may limit the longterm damage from economic weakness. We believe the key issue is to encourage firms to hire younger people. The overall jobless rate (8.3%) is well below the early 90s peak (10.7%), but the jobless rate among people aged 15-24 years (21.1% in 2011 as a whole, 22.2% in early 2012) is the highest since data began in 1983. Conversely, jobless rates among people aged 25-49 years, and 50+ years, (6.4% and 4.9% respectively on average in 2011) are far below the early 80s peaks (10.0% and 8.9% respectively) and early 90s peaks (8.8% and 9.2% respectively). A similar pattern is evident in many countries. Academic studies show that extended spells of unemployment among young people cast a long shadow over their lifetime employment and income prospects<sup>4</sup>.

**The minimum wage bites more heavily among younger workers**


The government has cut employment regulations among younger people and this year will freeze the minimum wage for people aged below 21 years. However, in our view, the size of the jobless crisis among younger people demands a far more aggressive response. In our view, one solution (alongside measures to improve education and skills) would be to sharply cut the minimum wage and employment regulations among younger workers — in effect, increasing the age-related tilt in the minimum wage to match the sharper age-related slope of pay levels in the economy. For the overall economy, the adult minimum wage (£6.08/hour in 2011, £6.19 from Oct-12) is only 48% of average hourly earnings (excluding overtime), which was £12.62 in 2011. Among people aged 30-49 years the ratio of minimum wage/average pay is below 45%. For these age groups, the minimum wage does not constrain pay for most workers. But, among people aged 18-21 years, the minimum wage is 71% of average pay, and this ratio has risen from 60% in 1999 (when the minimum wage was introduced at a time of economic strength). Given the disparities in ability between people, it is likely in our view that the minimum wage is stopping some firms hiring some young people (because the pay level that firms would be willing or able to pay is below the minimum wage). A lower minimum wage — implying lower pay — may seem overly harsh to some. But, in our view, the priority must be to get young people into work.

---

<sup>3</sup> This was suggested by Andrew Haldane of the BoE in a speech last August.


<sup>4</sup> See, for example, "Young people and the Great Recession", Bell and Blanchflower, Oxford Review of Economic Policy, 2011.

Figure 7. UK — Unemployment Rates By Age (Years), 1983-2011



Source: Citi Investment Research and Analysis

Figure 8. UK — Minimum Wage As Pct Median Hourly Earnings Excluding Overtime, By Age, 1999-2011



Sources: ONS, Low Pay Commission and Citi Investment Research and Analysis

**FX intervention is possible in theory but highly unlikely in practice**

**FX intervention to cap sterling.** The trade-weighted pound has risen by 8% since mid-11 to the highest since mid-09. Versus the euro, sterling has appreciated by 11% since mid-11, to the highest since late-08. MPC members have made it clear that the low pound is a crucial support for the UK economy, given persistent weakness in private spending and fiscal drag. In theory, the MPC can intervene in FX markets for monetary policy purposes, and hence could intervene to sell pounds as an alternative to QE. But, in practice, we regard this as highly unlikely, unless outright deflation threatens or is occurring (as in Japan and Switzerland). As a G20 member, the UK has signed up to support “*greater exchange rate flexibility*” and to “*refrain from competitive devaluation of currencies*”<sup>5</sup> Moreover, as an EU country, the UK has agreed that exchange rates are a matter of “*common concern*”.

**The UK at present is locked into a tough multi-year fiscal consolidation programme...**

**Temporary fiscal stimulus.** The UK coalition government is locked into a tough multi-year fiscal consolidation programme. The IMF estimates that the fiscal stance (cyclically adjusted primary balance) has tightened by 4.7% of GDP over the last three years and will tighten by a further 4.7% of GDP over the next five years. The major tax hikes are done but, on the government's own estimates, only 18% of the public spending cuts have been made so far (this will reach 29% at the end of the 2012/13 fiscal year). Moreover, the commitment to fiscal consolidation is right at the centre of the coalition agreement: without that, little policy agreement remains.

**...but the fiscal rules do allow considerable nearterm flexibility, and fiscal policy could provide a powerful nearterm stimulus**

Nevertheless, recent IMF research highlights that fiscal stimulus can provide a powerful boost to growth when the economy has plenty of slack<sup>6</sup>. Moreover, the UK's fiscal rules do allow a 1-2 year delay in fiscal consolidation, provided the commitment to tighten again subsequently is solid: the key rule is for the UK to achieve a cyclically adjusted current balance five years ahead, while the secondary rule is that the debt/GDP ratio must be falling in 2015/16. The government has already used this flexibility a little, responding to the lower growth outlook and lower estimates of potential growth by extending the planned fiscal consolidation beyond 2015. But ample temporary fiscal flexibility remains for 2012, 2013 and even 2014.


<sup>5</sup> See the G20 Cannes Summit Communiqué, November 4 2011. This could be interpreted as being consistent with a Swiss-style cap on the exchange rate.

<sup>6</sup> See “IMF Fiscal Monitor”, April 2012

**A move to temporary fiscal stimulus would need to be presented carefully...**

To be sure, temporary fiscal loosening would pose clear reputational and credibility problems for the government. It could easily appear to investors that the government is abandoning its fiscal consolidation programme altogether. In this case, even a modest and temporary fiscal stimulus might trigger such a big rise in gilt yields that there is little or no overall improvement in growth prospects. In addition, the coalition would find it politically very difficult to adopt even a temporary fiscal stimulus package: it would appear to be conceding the debate to Labour (who argued for slower fiscal austerity even when growth prospects were better). The argument that the drag on UK growth from the EMU crisis justifies temporary stimulus (or a delay in fiscal consolidation) may be too subtle to survive heated political debate.

**Figure 9. UK — Cyclically Adjusted Fiscal Deficit, Pct of GDP, Fiscal Years 2009/10-2016/17**



Sources: HM Treasury and Citi Investment Research and Analysis

**...but is an option, especially if the EMU crisis escalates and the UK gains outside endorsement for such a move**

Hence, we believe that temporary fiscal stimulus (or, at least, measures which effectively postpone austerity) would only come into play in cases of extreme economic weakness. The same applies to the related option of combining fiscal stimulus with permanent monetization of the extra deficit — ie a “helicopter” drop. Even then, the government would probably need some external endorsement (eg from the IMF) to overcome the political bias in favour of sticking with fiscal consolidation. In order to reinforce the temporary nature of any such move, it probably would be most effective via tax cuts or investment, leaving intact the planned gradual multi-year squeeze on public sector current spending<sup>7</sup>.

**Conclusion — the policy locker is not empty**

All these measures have various disadvantages, in terms of market distortions, or possible erosion of anti-inflation credibility, or lost fiscal credibility, or political difficulties. If the economy improves markedly, then the need for extra stimulus will diminish. But, even if economic conditions do not worsen further, we believe there is a good case for some of these measures (QE, credit easing, lower Bank Rate, measures to cut unemployment among younger workers). That case will strengthen — and the need for a wider range of stimulus measures may grow — if the downside risks from the EMU crisis escalate rapidly.

<sup>7</sup> The IMF has sketched out scenarios in which temporary tax cuts might be justified in last year's Article IV Report, published June 2011.



## Economic Indicators

Tue 15 May	<b>Trade Balance – Goods &amp; Services (Mar)</b>	<b>Forecast: £-2.5 billion</b>	<b>Prior: £-3.4 billion</b>
	The trade deficit has widened out again in early 2012, with an average monthly deficit of £2.9bn in January and February versus £2.4bn per month in Q4-11. Exports are weaker, while imports are stronger. We expect a slightly lower deficit for March but even so a figure in line with our forecast would put the overall Q1 deficit at £8.4bn, up from £7.1bn in Q4-11 and the highest trade deficit since Q4-2010.		
Wed 16 May	<b>Claimant Count Unemployment (Apr)</b>	<b>Forecast: +4,000 MoM, 4.9% Rate</b>	<b>Prior: +3,600 MoM, 4.9% Rate</b>
	<b>LFS Unemployment (Jan-Mar)</b>	<b>Forecast: -8,000 QoQ, 8.4% Rate</b>	<b>Prior: -35,000 QoQ, 8.3% Rate</b>
	The three-month average for the LFS measure showed unemployment falling in Dec-Feb, but the single month data (for February) showed unemployment rising 81,000 MoM after declines in December and January. We expect another modest rise (18K) in the single month data for March, which would leave the LFS jobless total roughly stable in Q1 as a whole. Both the LFS and claimant count jobless totals are likely to rise further in coming months.		
Tue 22 May	<b>Consumer Prices (Apr)</b>	<b>Forecast: 0.6% MoM, 3.1% YoY</b>	<b>Prior: 0.3% MoM, 3.5% YoY</b>
	<b>CPI Ex Food, Drink, Tobacco, Energy (Apr)</b>	<b>Forecast: 0.4% MoM, 2.0% YoY</b>	<b>Prior: 0.4% MoM, 2.5% YoY</b>
	<b>Retail Prices (Apr)</b>	<b>Forecast: 0.7% MoM, 3.5% YoY</b>	<b>Prior: 0.4% MoM, 3.6% YoY</b>
	<b>RPIX – Excludes Mortgages (Apr)</b>	<b>Forecast: 0.7% MoM, 3.5% YoY</b>	<b>Prior: 0.4% MoM, 3.7% YoY</b>
	Base effects from the very strong rise in the CPI a year earlier (it rose 1.0% MoM, biggest April rise since 1993) probably will bring the YoY CPI inflation rate sharply lower, despite a further rise of about 4p/litre in retail petrol prices. Such a figure would require the BoE Governor to write yet another letter to explain yet another inflation overshoot. With luck, this will be the last such letter, because CPI inflation is likely to drop below the 3% letter-writing threshold in coming months. But inflation has been persistently sticky in recent years.		

## Accessing Citi Economic Research

We want to highlight to you that our research is also available for your convenience through the following research distribution providers:

- Bloomberg using CTIR<GO>
- FactSet
- Thomson Reuters
- TheMarkets.com from Capital IQ

You are automatically able to view Citi research if you have entitlement on one of these systems. If you do not currently have Citi entitlement on these systems, please contact your provider representative to request access. These services are available to you in addition to Citi website access and research email services you may already receive from Citi directly.

If you have any questions or we can be of further assistance please do not hesitate to contact us.

Economic Calendar, 7 May — 25 May 2012

7 May	8 May	9 May	10 May	11 May
Bank Holiday in UK	RICS House Price Survey (Apr, 00:01)		Industrial Production (Mar) Feb 0.4% MoM, -2.3% YoY Mar -0.3% MoM, -2.6% YoY Manufacturing Output (Mar) Feb -1.1% MoM, -1.5% YoY Mar 0.9% MoM, -0.9% YoY	Producer Input Prices (Apr) Mar 1.7% MoM, 5.6% YoY Apr -1.5% MoM, 1.2% YoY Prod. Output Prices (Apr) Mar 0.6% MoM, 3.7% YoY Apr 0.7% MoM, 3.3% YoY Excluding Tax (Apr) Mar 0.5% MoM, 3.5% YoY Apr 0.6% MoM, 3.2% YoY Ex Food, Drink, Tobacco, Energy (Apr) Mar 0.1% MoM, 2.5% YoY Apr 0.6% MoM, 2.3% YoY
		MPC Meeting Starts	MPC Meeting Ends: Rates Unchanged at 0.5% QE Unchanged at £325bn  Norges Bank Outcome: Rates Unchanged at 1.50%	EU Commission Spring Economic Forecasts (10:00)
14 May	15 May	16 May	17 May	18 May
	Trade Balance – Goods & Services (Mar) Feb £-3.4bn MarE £-2.5bn	Claimant Count Unemployment (Apr) Mar +3,600 MoM, 4.9% Rate AprE +4,000 MoM, 4.9% Rate LFS Unemployment (Jan-Mar) Dec-Feb -35K QoQ, 8.3% Rate Jan-MarE -8K QoQ, 8.4% Rate		During The Weekend G-8 Summit Meeting of Heads of State & Gov't (Camp David, Maryland, US, May 19-20)
EuroGroup Meeting (Brussels)	EcoFin Meeting (Brussels)	BoE Inflation Report (10:30)		2012 Nato Summit (Chicago, May 20-21)
21 May	22 May	23 May	24 May	25 May
	Consumer Prices (Apr) Mar 0.3% MoM, 3.5% YoY AprE 0.6% MoM, 3.1% YoY CPI Ex Food, Drink, Tobacco, Energy (Apr) Mar 0.4% MoM, 2.5% YoY AprE 0.4% MoM, 2.0% YoY Retail Prices (Apr) Mar 0.4% MoM, 3.6% YoY AprE 0.7% MoM, 3.5% YoY RPIX – Ex Mortgages (Apr) Mar 0.4% MoM, 3.7% YoY AprE 0.7% MoM, 3.5% YoY  Public Sector Net Borrowing – Ex Costs of Financial Intervent'n (Apr)	Retail Sales Volumes (Apr)  CBI Industrial Trends (May) (11:00)  MPC Minutes (May 10)  BoE Agents' Summary of Business Conditions (May)  Informal Meeting of European Council of EU Heads of State & Gov't (Brussels)	GDP (Q1, 2 <sup>nd</sup> Release)  Service Sector Output (Mar)  Business Investment (Q1, Provisional)  Migration Statistics Quarterly Report (May)	

E Citi estimate. B Billion. P Provisional. R Revised. Note: All data are released at 9.30 a.m., except those marked otherwise.

Sources: BoE, CBI, CML, ONS, national sources and Citi Investment Research and Analysis.



## Appendix A-1

### Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

### IMPORTANT DISCLOSURES

---

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

---

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research & Analysis product ("the Product"), please contact Citi Investment Research & Analysis, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

### NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd

Michael Saunders; Ann O'Kelly

### OTHER DISCLOSURES

---

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

---

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research & Analysis (CIRA) does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of CIRA to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

---

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

---

**Important Disclosures for Morgan Stanley Smith Barney LLC Customers:** Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Investment Research & Analysis (CIRA) research report. Ask your Financial Advisor or use

smithbarney.com to view any available Morgan Stanley research reports in addition to CIRA research reports.

Important disclosure regarding the relationship between the companies that are the subject of this CIRA research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at [www.morganstanleysmithbarney.com/researchdisclosures](http://www.morganstanleysmithbarney.com/researchdisclosures). For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to [www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures) and [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

This CIRA research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of CIRA. This could create a conflict of interest.

---

**The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.**

The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 110-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd=A03030&pageDiv=02>. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the

meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different CIRA ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to CIRA's Products can be found at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs), CIRA concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual CIRA analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. CIRA simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by CIRA analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints.

CIRA product may source data from dataCentral. dataCentral is a CIRA proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

---

© 2012 Citigroup Global Markets Inc. Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

EU20511A

---